Hims & Hers Health (HIMS) inked a deal with Eli Lilly (LLY) on Friday to sell the company's obesity drugs, further entrenching itself in the branded GLP-1 space. Hims stock surged 8% to 26, while Lilly stock dipped less than 1% to 1,354.49. The deal will sees Hims sell Lilly's Zepbound and Foundayo on its telehealth platform. It follows a…

Copyright ©2026 Investor's Business Daily, LLC. All rights reserved. 87990cbe856818d5eddac44c7b1cdeb8